The KICKSTART study is evaluating an investigational immunotherapy for NSCLC to be added on
to an approved immunotherapy.
To learn more details about this research study, please download the brochure that may apply to you or your loved one: To learn about participating in the KICKSTART study or to see if there is a research study location near you, please scroll down or click on the page links.
Any adult who has been diagnosed with stage IIIb or stage IV non-small cell lung cancer.
These questions are directed to the person who will participate in the research study if they qualify, so "you" as used in the pre-qualifying questionnaire refers to that person.
No. You may take the pre-qualifying questionnaire just to see if you might pre-qualify. Participation in a research study is completely voluntary at every step in the process.
Why is the KICKSTART Study Important?
According to the American Lung Association, non-small cell lung cancer (NSCLC) makes up over 85% of
all lung cancer cases. Although progress has been made, lung cancer is still the leading cause of cancer
deaths, causing more deaths than breast, prostate, and colon cancers combined.
Lung cancer research is necessary to develop new medications to help provide better treatment options. Before new medications can be approved for public use, they must be tested in research studies like this one.
Although there are many definitions, a clinical research study is generally considered to be health-related
clinical research in people with a specific condition using a pre-defined written protocol.
Click here to learn more about clinical research.